Finally, to evaluate the clinical relevance of c-MYC methylation by SMYD3, we assessed c-MYC K158/K163Me levels by immunohistochemistry in normal and cancer tissues from CRC patients with advanced-stage cancer. Here, SMYD3 is linked to colorectal carcinoma.